The extracellular matrix of human bone marrow adipocytes and glucose concentration differentially alter mineralization quality without impairing osteoblastogenesis.

AGEs, Advanced glycation end-products BM-MSC, Bone marrow mesenchymal stromal cell BMAd, Bone marrow adipocyte ECM, Extracellular matrix ECMBMAd HG, Extracellular matrix obtained from BMAds cultured in HG concentration ECMBMAd LG, Extracellular matrix obtained from BMAds cultured in LG concentration ECMBMAd, Extracellular matrix obtained from BMAds Extracellular matrix GAG, glycosaminoglycan HA, hydroxyapatite HG, High glucose Hyperglycemia LG, Low glucose LGM, Low glucose and mannitol Marrow adipocytes Osteoblast Osteoporosis Skeletal mesenchymal stromal cells T2D, Type 2 diabetes

Journal

Bone reports
ISSN: 2352-1872
Titre abrégé: Bone Rep
Pays: United States
ID NLM: 101646176

Informations de publication

Date de publication:
Dec 2022
Historique:
received: 25 07 2022
revised: 09 09 2022
accepted: 19 09 2022
entrez: 3 10 2022
pubmed: 4 10 2022
medline: 4 10 2022
Statut: epublish

Résumé

Bone marrow adipocytes (BMAds) accrue in various states of osteoporosis and interfere with bone remodeling through the secretion of various factors. However, involvement of the extracellular matrix (ECM) produced by BMAds in the impairment of bone marrow mesenchymal stromal cell (BM-MSC) osteoblastogenesis has received little attention. In type 2 diabetes (T2D), skeletal fragility is associated with several changes in bone quality that are incompletely understood, and BMAd quantity increases in relationship to poor glycemic control. Considering their altered phenotype in this pathophysiological context, we aimed to determine the contribution of the ECM of mature BMAds to osteoblastogenesis and mineralization quality in the context of chronic hyperglycemia. Human BM-MSCs were differentiated for 21 days in adipogenic medium containing either a normoglycemic (LG, 5.5 mM) or a high glucose concentration (HG, 25 mM). The ECM laid down by BMAds were devitalized through cell removal to examine their impact on the proliferation and differentiation of BM-MSCs toward osteoblastogenesis in LG and HG conditions. Compared to control plates, both adipocyte ECMs promoted cell adhesion and proliferation. As shown by the unmodified RUNX2 and osteocalcin mRNA levels, BM-MSC commitment in osteoblastogenesis was hampered by neither the hyperglycemic condition nor the adipocyte matrices. However, adipocyte ECMs or HG condition altered the mineralization phase with perturbed expression levels of type 1 collagen, MGP and osteopontin. Despite higher ALP activity, mineralization levels per cell were decreased for osteoblasts grown on adipocyte ECMs compared to controls. Raman spectrometry revealed that culturing on adipocyte matrices specifically prevents type-B carbonate substitution and favors collagen crosslinking, in contrast to exposure to HG concentration alone. Moreover, the mineral to organic ratio was disrupted according to the presence of adipocyte ECM and the glucose concentration used for adipocyte or osteoblast culture. HG concentration and adipocyte ECM lead to different defects in mineralization quality, recapitulating contradictory changes reported in T2D osteoporosis. Our study shows that ECMs from BMAds do not impair osteoblastogenesis but alter both the quantity and quality of mineralization partly in a glucose concentration-dependent manner. This finding sheds light on the involvement of BMAds, which should be considered in the compromised bone quality of T2D and osteoporosis patients more generally.

Identifiants

pubmed: 36187598
doi: 10.1016/j.bonr.2022.101622
pii: S2352-1872(22)00456-9
pmc: PMC9519944
doi:

Types de publication

Journal Article

Langues

eng

Pagination

101622

Informations de copyright

© 2022 The Authors.

Déclaration de conflit d'intérêts

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Stephanie LUCAS reports financial support was provided by MSD Avenir Foundation.

Références

Stem Cells Int. 2016;2016:6397820
pubmed: 26770210
Front Cell Dev Biol. 2021 Nov 29;9:770705
pubmed: 34912805
Adv Mater. 2010 Jul 27;22(28):3042-7
pubmed: 20518038
Biomater Sci. 2017 Dec 19;6(1):168-178
pubmed: 29167844
Calcif Tissue Int. 2017 Jun;100(6):565-574
pubmed: 28246932
Am J Physiol. 1999 Nov;277(5):F750-5
pubmed: 10564238
J Cell Physiol. 2018 Jan;233(1):387-395
pubmed: 28272740
Calcif Tissue Int. 2020 Sep;107(3):281-293
pubmed: 32642787
Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10139-44
pubmed: 8816765
Bone. 2016 Jan;82:2-8
pubmed: 26027505
PLoS One. 2012;7(6):e38752
pubmed: 22701703
Biomed Mater. 2017 Jun 06;12(3):035008
pubmed: 28351999
Sci Rep. 2014 Jan 13;4:3663
pubmed: 24413028
Nat Commun. 2020 Jun 18;11(1):3097
pubmed: 32555194
J Bone Miner Res. 2016 May;31(5):1070-81
pubmed: 26636271
Acta Biomater. 2018 Jun;73:154-166
pubmed: 29684623
J Cell Biochem. 2006 Oct 1;99(2):411-24
pubmed: 16619259
Cytotherapy. 2010 Dec;12(8):992-1005
pubmed: 20807021
J Biomed Mater Res A. 2014 Sep;102(9):3237-42
pubmed: 24167147
J Cell Physiol. 2018 Sep;233(9):6853-6865
pubmed: 29319174
Bone. 2018 May;110:204-214
pubmed: 29438824
Cell Tissue Res. 2014 Oct;358(1):249-56
pubmed: 24859221
Calcif Tissue Int. 2005 Sep;77(3):167-74
pubmed: 16075362
J Cell Biochem. 2003 Oct 1;90(2):234-43
pubmed: 14505340
Bone. 2021 Jul;148:115962
pubmed: 33862262
J Bone Miner Res. 2007 Dec;22(12):1943-56
pubmed: 17680726
Bone. 2001 Jan;28(1):21-8
pubmed: 11165939
J Clin Endocrinol Metab. 2021 Aug 18;106(9):e3592-e3602
pubmed: 33974069
Calcif Tissue Int. 1998 Dec;63(6):475-81
pubmed: 9817941
J Biomed Mater Res A. 2012 Apr;100(4):1089-96
pubmed: 22318934
Stem Cells. 2014 Jun;32(6):1649-60
pubmed: 24496952
Eur J Clin Invest. 1992 Dec;22(12):805-12
pubmed: 1478252
Curr Osteoporos Rep. 2019 Dec;17(6):455-464
pubmed: 31713179
Bone. 2019 Oct;127:207-214
pubmed: 31229674
J Cell Biochem. 2013 Nov;114(11):2595-602
pubmed: 23757055
Biomaterials. 2012 Mar;33(7):2025-31
pubmed: 22177287
Bone. 2021 Dec;153:116101
pubmed: 34245934
PLoS One. 2013 Jun 18;8(6):e65943
pubmed: 23823126
Int J Mol Sci. 2020 Jul 30;21(15):
pubmed: 32751654
Am J Physiol Cell Physiol. 2020 Jan 1;318(1):C111-C124
pubmed: 31532718
Exp Ther Med. 2022 Mar;23(3):235
pubmed: 35222712
Sci Rep. 2018 Apr 12;8(1):5881
pubmed: 29651097
J Biol Chem. 2014 Apr 18;289(16):11410-11420
pubmed: 24569987
Cell Mol Life Sci. 2013 Jul;70(13):2331-49
pubmed: 23178849
Front Endocrinol (Lausanne). 2019 Sep 10;10:607
pubmed: 31551934
Acta Biomater. 2013 Nov;9(11):8921-31
pubmed: 23816649
J Pharm Sci. 2011 Feb;100(2):441-50
pubmed: 20653053
Osteoporos Int. 2006 Oct;17(10):1514-23
pubmed: 16770520
Curr Osteoporos Rep. 2019 Oct;17(5):291-300
pubmed: 31392668
Sci Rep. 2016 Jul 01;6:28889
pubmed: 27363302
Endocrinology. 2007 Sep;148(9):4267-75
pubmed: 17540722
Stem Cells Dev. 2010 Jul;19(7):1095-107
pubmed: 19737070
J Bone Miner Res. 2021 Feb;36(2):334-346
pubmed: 32970898
Curr Opin Endocrinol Diabetes Obes. 2021 Aug 1;28(4):360-370
pubmed: 34183538
Front Biosci (Landmark Ed). 2012 Jan 01;17(1):100-28
pubmed: 22201735
Bone. 2012 Jan;50(1):276-88
pubmed: 22086137
Stem Cells Int. 2016;2016:9674614
pubmed: 27057179
Curr Osteoporos Rep. 2014 Dec;12(4):454-64
pubmed: 25240579
Calcif Tissue Int. 2016 Sep;99(3):289-301
pubmed: 27209312
Diabetes. 2018 Jul;67(7):1380-1394
pubmed: 29703845
J Bone Miner Res. 2009 Sep;24(9):1565-71
pubmed: 19419303
Connect Tissue Res. 2016;57(1):28-37
pubmed: 26539896
Calcif Tissue Int. 2017 May;100(5):461-475
pubmed: 27364342
Biomaterials. 2017 May;127:75-88
pubmed: 28279923
Am J Physiol. 1993 Oct;265(4 Pt 2):F530-6
pubmed: 8238381
BMC Cell Biol. 2015 Mar 13;16:9
pubmed: 25887471
Best Pract Res Clin Endocrinol Metab. 2021 Jul;35(4):101545
pubmed: 33966979
Analyst. 2011 Jun 21;136(12):2471-81
pubmed: 21541414
J Biol Chem. 2009 Nov 6;284(45):31164-73
pubmed: 19762920
Bone. 2017 Apr;97:38-42
pubmed: 28043896
Front Cell Dev Biol. 2021 Nov 30;9:760532
pubmed: 34917612
Mater Sci Eng C Mater Biol Appl. 2019 Dec;105:110039
pubmed: 31546422
J Diabetes Res. 2014;2014:453940
pubmed: 24812633
Mol Cell Biochem. 2010 May;338(1-2):115-22
pubmed: 19949837
Bone. 2014 Mar;60:26-32
pubmed: 24269519
Osteoporos Int. 2006;17(3):319-36
pubmed: 16341622
Eur J Endocrinol. 2018 Oct 01;179(4):R165-R182
pubmed: 30299886
Bone. 2018 Sep;114:32-39
pubmed: 29857063
Ann N Y Acad Sci. 2017 Dec;1410(1):93-106
pubmed: 29265417
FASEB J. 2011 May;25(5):1474-85
pubmed: 21248241
J Mech Behav Biomed Mater. 2017 Jan;65:264-273
pubmed: 27608424
Tissue Eng Part A. 2018 Sep;24(17-18):1377-1389
pubmed: 29667532
J Bone Miner Res. 2018 May;33(5):921-929
pubmed: 29281127
PLoS One. 2015 Jun 05;10(6):e0127973
pubmed: 26046792
Tissue Eng Part B Rev. 2017 Jun;23(3):268-280
pubmed: 27846781
Bone. 2006 Dec;39(6):1236-43
pubmed: 16860007
JBMR Plus. 2021 Dec 16;6(2):e10583
pubmed: 35229063
J Bone Miner Res. 2004 Dec;19(12):2000-4
pubmed: 15537443
Curr Osteoporos Rep. 2018 Jun;16(3):205-215
pubmed: 29611037
Front Endocrinol (Lausanne). 2016 Jun 30;7:85
pubmed: 27445987

Auteurs

Laura Entz (L)

Marrow Adiposity and Bone Lab, MABLab-ULR4490, Univ. Littoral Côte d'Opale F-62200 Boulogne-sur-Mer, Univ. Lille F-59000 Lille, CHU Lille, F-59000 Lille, France.

Guillaume Falgayrac (G)

Marrow Adiposity and Bone Lab, MABLab-ULR4490, Univ. Littoral Côte d'Opale F-62200 Boulogne-sur-Mer, Univ. Lille F-59000 Lille, CHU Lille, F-59000 Lille, France.

Christophe Chauveau (C)

Marrow Adiposity and Bone Lab, MABLab-ULR4490, Univ. Littoral Côte d'Opale F-62200 Boulogne-sur-Mer, Univ. Lille F-59000 Lille, CHU Lille, F-59000 Lille, France.

Gilles Pasquier (G)

Marrow Adiposity and Bone Lab, MABLab-ULR4490, Univ. Littoral Côte d'Opale F-62200 Boulogne-sur-Mer, Univ. Lille F-59000 Lille, CHU Lille, F-59000 Lille, France.

Stéphanie Lucas (S)

Marrow Adiposity and Bone Lab, MABLab-ULR4490, Univ. Littoral Côte d'Opale F-62200 Boulogne-sur-Mer, Univ. Lille F-59000 Lille, CHU Lille, F-59000 Lille, France.

Classifications MeSH